RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
        • 주제분류
        • 발행연도
        • 작성언어
        • 저자
          펼치기

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        연속요법의 Helicobacter pylori 제균율 - 3차 기관에서의 8년간의 전향적 연구

        윤기철 ( Kichul Yoon ),김나영 ( Nayoung Kim ) 대한소화기학회 2019 대한소화기학회지 Vol.73 No.2

        목적: 한국에서 표준 3제요법에 의한 H. pylori의 제균율은 낮은 실정이다. 일차 제균 치료로서의 연속요법(sequential therapy)은 현실적인 대안으로 제시되어 왔다. 본 전향적 연구에서는 연속요법의 연도별 제균율 변화 양상을 확인하고자 하였다. 대상 및 방법: 2010년부터 2018년까지 983명의 환자가 치료 의도자 분석(intention to treat) 및 복용순응자 분석 대상이 되었다. 10일 연속요법은 최초 5일간 esomeprazole 40 mg b.i.d, amoxicillin 1 g b.i.d 투약 후 esomeprazole 40 mg b.i.d, clarithromycin 500 mg b.i.d, metronidazole 500 mg t.i.d를 5일간 추가 투약하였다. 추적 시 요소호기 검사, 요소 분해 검사, 또는 조직학적 검사로 제균 여부를 확인하였으며 약물 순응도와 부작용 발생 여부 또한 조사하였다. 결과: 치료의도자 분석과 복용순응자 분석의 제균율은 각각 69.9% (687명/983명) 및 87.1% (657명/754명)였다. 2010년부터 2018년까지 각 연도별 치료의도자 제균율은 시간에 따른 유의한 변화 양상 없이 유사하게 유지되었으며(p for trend=0.167), 복용순응자 제균율은 증가하는 경향을 보였다 (p for trend=0.042). 약물 부작용은 41.7% (410명)의 환자에서 보고되었다. 결론: 한국에서의 높은 항생제 내성률에도 불구하고 연속요법의 제균율은 8년간 감소하지 않고 유지되었다. Background/Aims: The Helicobacter pylori (H. pylori) eradication rate of standard triple therapy is unsatisfactory in Korea, and sequential therapy (SQT) has been suggested to be a practical first-line alternative regimen. The aim of this prospective study was to document changes in annual eradication rates of SQT. Methods: A total of 983 H. pylori-positive subjects were enrolled from 2010 to 2018 and their data were subjected to intention-to-treat (ITT) and per-protocol (PP) analysis. All subjects received 10-day sequential therapy consisting of 40 mg esomeprazole and 1 g amoxicillin b.i.d for 5 days followed by 40 mg esomeprazole b.i.d, 500 mg clarithromycin b.i.d and 500 mg metronidazole t.i.d for 5 days. The <sup>13</sup>C-urea breath test, rapid urease test (CLO test<sup>®</sup>), and histology were used to confirm eradication. Compliance and side effects were also investigated. Results: ITT and PP eradication rates of SQT were 69.9% (687 of 983) and 87.1% (657 of 754), respectively. The annual eradication rate of ITT remained consistent over the 8-year study period (p for trend=0.167), whereas PP analysis showed the eradication rate increased (p for trend=0.042). The overall adverse event rate for SQT was 41.7% (410 subjects). Conclusions: Despite high antibiotic resistance rates in Korea, the eradication rate of SQT did not decrease over the 8-year study period. (Korean J Gastroenterol 2019;73:99-104)

      • KCI등재

        헬리코박터 파일로리 제균에 의한 위축성 위염과 장상피화생의 가역성

        윤기철 ( Kichul Yoon ),김나영 ( Nayoung Kim ) 대한소화기학회 2018 대한소화기학회지 Vol.72 No.3

        Although there are many guidelines recommending Helicobacter pylori (H. pylori) eradication therapy for atrophic gastritis (AG) and intestinal metaplasia (IM), there have been contradictory reports regarding the reversibility of precancerous lesions such as AG and IM after eradication of H. pylori. There have been many reports that have shown AG seems to improve upon eradication of H. pylori to some extent. In contrast, IM has been regarded as 'the point of no return' according to previous reports. However, as recent studies have suggested the improvement of intestinal metaplasia as well, early eradication therapy for reversible histological status is important and necessary for the prevention of gastric cancer. In this review, we focused on the progress of gastritis resulting in AG and IM mainly by H. pylori, the relationship of AG and IM with gastric cancer, the subtype of IM, and the reversibility of AG and IM by eradication of H. pylori. Finally, we introduced the recent extension of indications for H. pylori eradication with coverage by medical insurance, which was published by the Korean Ministry of Health and Welfare in January 2018. (Korean J Gastroenterol 2018;72:104-115)

      • KCI등재

        복부 팽만 환자에서 리팍시민의 임상적 효과

        윤기철 ( Kichul Yoon ),김나영 ( Nayoung Kim ),이주엽 ( Ju Yup Lee ),오동현 ( Dong Hyun Oh ),서아영 ( A Young Seo ),윤창용 ( Chang Yong Yun ),윤혁 ( Hyuk Yoon ),신철민 ( Cheol Min Shin ),박영수 ( Young Soo Park ),이동호 ( Dong Ho 대한소화기학회 2018 대한소화기학회지 Vol.72 No.3

        Background/Aims: Abdominal bloating is a troublesome complaint due to insufficient understanding of the pathophysiology. The aim of this study was to evaluate the efficacy of rifaximin in reducing bloating associated with functional gastrointestinal disorders (FGIDs). Methods: A total of 63 patients were treated with rifaximin for FGIDs with bloating or gas-related symptoms between 2007 and 2013 at Seoul National University Bundang Hospital. Rifaximin was administered at a dose between 800 mg/day and 1,200 mg/day for 5 to 14 days. The proportion of patients who had adequate relief of global FGID symptoms and FGID-related bloating was retrospectively assessed. The response was recorded when the symptoms were reduced by at least 50% at the follow-up after treatment cessation. Results: The mean age was 56.8±14.2 years; 49.2% were females. According to Rome III criteria, 20.6% (13/63) had irritable bowel syndrome (IBS) with constipation, 9.5% (6/63) had IBS with diarrhea, 4.8% (3/63) had mixed IBS, 23.8% (15/63) had functional dyspepsia, and 12.7% (8/63) had functional bloating. Of the 51 subjects who were followed-up, 30 (58.8%) had adequate relief of global FGID symptoms and 26 (51.0%) experienced improvement of abdominal bloating after rifaximin treatment. The proportion of female was slightly higher in non-response group than in the response group (60.0% vs. 34.6%, p=0.069). Otherwise, there was no difference between the two groups. Conclusions: Despite the limitations of this retrospective study, our data confirms that rifaximin may be beneficial for abdominal bloating. Further prospective clinical trial with a larger cohort is needed. (Korean J Gastroenterol 2018;72:121-127)

      • KCI등재

        도플러 저해상도 레이다의 탐지성능 향상을 위한 속도 기반 하이브리드 도플러 처리 기법

        권대현(Daihyun Kwon),조병래(Byung-Lae Cho),윤기철(Kichul Yoon),김관성(Kwan Sung Kim),김찬홍(Chan-Hong Kim) 한국정보기술학회 2023 한국정보기술학회논문지 Vol.21 No.2

        In this paper, the velocity based hybrid doppler processing method is proposed to increase SIR. The proposed method uses two filters, MTI and FIR, for each velocity interval. The proposed algorithm uses a velocity boundary and two parameters are specified by Monte Carlo simulation that determine this value. The first is the ambiguity velocity which has a linear relationship with the velocity boundary. The second is the standard deviation of the FIR filter, and we investigate that it is logarithmic with the velocity boundary. Since the detection probability increases as the SIR increases, the detection performance improves as the SIR increases. Finally, the proposed algorithm was verified through simulation.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼